Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,otherCurrentAssets,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,changeToAccountReceivables,changeToNetincome,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,DYAI,25688483.0,27554200,1808098,,-3294949,,-3294949,1554007,69758,-3292347,-3292347,,,,,,0,460520,3752867,390762,-2602,,-3294949,-3294949,98549890.0,2593729.0,25688483.0,842248.0,28282212.0,39808.0,-53971300.0,-18929915.0,6151.0,13055558.0,2593729.0,27991352.0,284709.0,14177441.0,542164.0,1473813.0,,-5783940,1199687,-5783940,115800,-192745,115800,-7581487,-6834,-1906513,-131800,513294,25397623.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,6.3,1630506690,-0.01999998,6.38,6.4,6.23,48437,USD,NCM,173591472,-14400000,False,False,REGULAR,2,-0.3164554,6.23 - 6.4,us_market,0,"Dyadic International, Inc.",6.32,6.29,6.3,12,13,finmb_4272801,NasdaqCM,"Dyadic International, Inc.",USD,3877743,1085516,3.15,1.0,3.15 - 8.78,-2.4799995,-0.2824601,3.15,8.78,1620936000,1636578000,1637010000,-0.379,-0.12,-0.33,-19.090908,0.932,4.209722,2.0902781,0.4965359,4.4652176,1.8347826,0.41090554,-52.500004,6.759657,15,America/New_York,EDT,-0.02,,,8.78,3.15,4.21,4.47,3.88M,1.09M,27.55M,,9.36M,29.83%,25.45%,722.96k,2.42,3.74%,2.62%,1.19M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-622.99%,-21.37%,-34.72%,1.75M,0.06,46.00%,176.99k,,-10.41M,-0.38,,27.23M,0.99,,,10.79,0.93,-6.48M,-2.92M,Value,33477-5094,Healthcare,6,8,8,"Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.",Jupiter,561 743 8333,FL,9,1609372800,1625097600,6,United States,http://www.dyadic.com,86400,8,140 Intracoastal Pointe Drive,561 743 8343,Biotechnology,Suite 404
t-1,DYAI,28446561.0,27554200,1010451,,-1928895,,-1960213,1312682,90337,-2232796,-2232796,,,,,,31318,345917,2578713,255580,303901,,-1960213,-1960213,98013079.0,1625871.0,28446561.0,123016.0,30072432.0,39748.0,-50676351.0,-18929915.0,6225.0,20637045.0,1625871.0,29781498.0,284709.0,8457452.0,406446.0,1013099.0,,38209,-22388,38209,24660,2421,24660,-1225536,-1421,-1286984,505063,188133,28155627.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,6.3,1630506690,-0.01999998,6.38,6.4,6.23,48437,USD,NCM,173591472,-14400000,False,False,REGULAR,2,-0.3164554,6.23 - 6.4,us_market,0,"Dyadic International, Inc.",6.32,6.29,6.3,12,13,finmb_4272801,NasdaqCM,"Dyadic International, Inc.",USD,3877743,1085516,3.15,1.0,3.15 - 8.78,-2.4799995,-0.2824601,3.15,8.78,1620936000,1636578000,1637010000,-0.379,-0.12,-0.33,-19.090908,0.932,4.209722,2.0902781,0.4965359,4.4652176,1.8347826,0.41090554,-52.500004,6.759657,15,America/New_York,EDT,-0.02,,,8.78,3.15,4.21,4.47,3.88M,1.09M,27.55M,,9.36M,29.83%,25.45%,722.96k,2.42,3.74%,2.62%,1.19M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-622.99%,-21.37%,-34.72%,1.75M,0.06,46.00%,176.99k,,-10.41M,-0.38,,27.23M,0.99,,,10.79,0.93,-6.48M,-2.92M,Value,33477-5094,Healthcare,6,8,8,"Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.",Jupiter,561 743 8333,FL,9,1609372800,1625097600,6,United States,http://www.dyadic.com,86400,8,140 Intracoastal Pointe Drive,561 743 8343,Biotechnology,Suite 404
t-2,DYAI,29994454.0,27554200,986054,,-2499499,,-2499499,1643493,149432,-2592548,-2592548,112433.0,,,,,0,416361,3008909,266929,93049,,-2499499,-2499499,97600771.0,1751250.0,29994454.0,153855.0,31745704.0,39736.0,-48716138.0,-18929915.0,5558.0,21862581.0,1751250.0,31740146.0,,8544815.0,913252.0,976762.0,,11456000,-103656,11456000,67,538827,67,10081032,8444,-1383479,-173810,354043,29988896.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,6.3,1630506690,-0.01999998,6.38,6.4,6.23,48437,USD,NCM,173591472,-14400000,False,False,REGULAR,2,-0.3164554,6.23 - 6.4,us_market,0,"Dyadic International, Inc.",6.32,6.29,6.3,12,13,finmb_4272801,NasdaqCM,"Dyadic International, Inc.",USD,3877743,1085516,3.15,1.0,3.15 - 8.78,-2.4799995,-0.2824601,3.15,8.78,1620936000,1636578000,1637010000,-0.379,-0.12,-0.33,-19.090908,0.932,4.209722,2.0902781,0.4965359,4.4652176,1.8347826,0.41090554,-52.500004,6.759657,15,America/New_York,EDT,-0.02,,,8.78,3.15,4.21,4.47,3.88M,1.09M,27.55M,,9.36M,29.83%,25.45%,722.96k,2.42,3.74%,2.62%,1.19M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-622.99%,-21.37%,-34.72%,1.75M,0.06,46.00%,176.99k,,-10.41M,-0.38,,27.23M,0.99,,,10.79,0.93,-6.48M,-2.92M,Value,33477-5094,Healthcare,6,8,8,"Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.",Jupiter,561 743 8333,FL,9,1609372800,1625097600,6,United States,http://www.dyadic.com,86400,8,140 Intracoastal Pointe Drive,561 743 8343,Biotechnology,Suite 404
t-3,DYAI,32093205.0,27554200,1116163,,-2651422,,-2651422,1475232,-99969,-2766319,-2766319,74955.0,,,,,0,524271,3290590,624240,114897,,-2651422,-2651422,97200023.0,1638416.0,32093205.0,116331.0,33731621.0,39736.0,-46216639.0,-18929915.0,6116.0,11781549.0,1638416.0,33725505.0,,20053019.0,1291423.0,1143961.0,16261.0,8930229,245778,8930229,55743,-172362,55743,7084718,6330,-1907584,-3146,673568,32087089.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,6.3,1630506690,-0.01999998,6.38,6.4,6.23,48437,USD,NCM,173591472,-14400000,False,False,REGULAR,2,-0.3164554,6.23 - 6.4,us_market,0,"Dyadic International, Inc.",6.32,6.29,6.3,12,13,finmb_4272801,NasdaqCM,"Dyadic International, Inc.",USD,3877743,1085516,3.15,1.0,3.15 - 8.78,-2.4799995,-0.2824601,3.15,8.78,1620936000,1636578000,1637010000,-0.379,-0.12,-0.33,-19.090908,0.932,4.209722,2.0902781,0.4965359,4.4652176,1.8347826,0.41090554,-52.500004,6.759657,15,America/New_York,EDT,-0.02,,,8.78,3.15,4.21,4.47,3.88M,1.09M,27.55M,,9.36M,29.83%,25.45%,722.96k,2.42,3.74%,2.62%,1.19M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-622.99%,-21.37%,-34.72%,1.75M,0.06,46.00%,176.99k,,-10.41M,-0.38,,27.23M,0.99,,,10.79,0.93,-6.48M,-2.92M,Value,33477-5094,Healthcare,6,8,8,"Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.",Jupiter,561 743 8333,FL,9,1609372800,1625097600,6,United States,http://www.dyadic.com,86400,8,140 Intracoastal Pointe Drive,561 743 8343,Biotechnology,Suite 404
